Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tandem Diabetes Care (TNDM) Invested Capital (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Invested Capital for 13 consecutive years, with $133.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Invested Capital fell 52.22% year-over-year to $133.0 million, compared with a TTM value of $133.0 million through Sep 2025, down 52.22%, and an annual FY2024 reading of $303.8 million, down 3.15% over the prior year.
  • Invested Capital was $133.0 million for Q3 2025 at Tandem Diabetes Care, roughly flat from $133.3 million in the prior quarter.
  • Across five years, Invested Capital topped out at $449.6 million in Q2 2022 and bottomed at $133.0 million in Q3 2025.
  • Average Invested Capital over 5 years is $320.4 million, with a median of $314.0 million recorded in 2023.
  • The sharpest move saw Invested Capital surged 51.28% in 2021, then tumbled 52.22% in 2025.
  • Year by year, Invested Capital stood at $433.1 million in 2021, then rose by 1.58% to $439.9 million in 2022, then decreased by 28.71% to $313.6 million in 2023, then fell by 3.15% to $303.8 million in 2024, then plummeted by 56.23% to $133.0 million in 2025.
  • Business Quant data shows Invested Capital for TNDM at $133.0 million in Q3 2025, $133.3 million in Q2 2025, and $196.0 million in Q1 2025.